Coeptis Therapeutics CMO Resigns; Interim Appointed
Ticker: COEPW · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1759186
Sentiment: neutral
Topics: management-change, executive-departure, personnel
TL;DR
CMO out, new interim CMO in at Coeptis. No drama reported.
AI Summary
On December 3, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing the resignation of Dr. Robert L. Johnson as Chief Medical Officer, effective December 2, 2024. The company also announced the appointment of Dr. David M. Weiner as interim Chief Medical Officer. No disagreements with Dr. Johnson's departure were noted.
Why It Matters
This change in key leadership within the medical department could impact the company's research and development direction and execution.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in a clinical-stage company, can introduce uncertainty regarding strategic direction and operational continuity.
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- Dr. Robert L. Johnson (person) — Resigning Chief Medical Officer
- Dr. David M. Weiner (person) — Appointed interim Chief Medical Officer
- December 3, 2024 (date) — Date of Report
- December 2, 2024 (date) — Effective date of resignation
FAQ
Who has been appointed as the interim Chief Medical Officer for Coeptis Therapeutics Holdings, Inc.?
Dr. David M. Weiner has been appointed as the interim Chief Medical Officer.
When was Dr. Robert L. Johnson's resignation as Chief Medical Officer effective?
Dr. Robert L. Johnson's resignation was effective December 2, 2024.
Did Coeptis Therapeutics Holdings, Inc. state any disagreements with Dr. Johnson's departure?
No, the filing states that there were no disagreements between Dr. Johnson and the company regarding his departure.
What is the filing date of this 8-K report?
The filing date of this 8-K report is December 4, 2024, with the earliest event reported on December 3, 2024.
What is the former name of Coeptis Therapeutics Holdings, Inc.?
The former name of Coeptis Therapeutics Holdings, Inc. was Bull Horn Holdings Corp.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-04 17:00:09
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
- $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
Filing Documents
- coeptis_8k.htm (8-K) — 31KB
- coeptis_ex9901.htm (EX-99.1) — 12KB
- 0001683168-24-008519.txt ( ) — 267KB
- coep-20241203.xsd (EX-101.SCH) — 3KB
- coep-20241203_def.xml (EX-101.DEF) — 29KB
- coep-20241203_lab.xml (EX-101.LAB) — 36KB
- coep-20241203_pre.xml (EX-101.PRE) — 26KB
- coeptis_8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events On December 3, 2024, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis") issued a press release announcing the entering into of a letter of intent with NexGenAI Holding Group Inc. for the acquisition by Coeptis of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates ("NexGenAI") that offers AI-powered marketing software and robotic process automation ("RPA") capabilities. The closing of this transaction is subject to preparation and execution of definitive documents . A copy of the press release is included with the Current Report on Form 8-K .
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No . Description 99.1 Press Release, dated December 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: December 4, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3